Medivir AB to Receive Two Milestone Payments Amounting to 17 Million Euros in the Tibotec HCV Collaboration

STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Medivir (STO:MVIRB) is collaborating with Tibotec Pharmaceuticals Ltd to develop HCV NS3/4A Protease Inhibitors for the treatment of chronic hepatitis C virus (HCV) infection.